Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma

J Bellmunt; Ronald de Wit; DJ Vaughn; Y Fradet; JL Lee; L Fong; NJ Vogelzang; MA Climent; DP Petrylak; TK Choueiri; A Necchi; W Gerritsen; H Gurney; DI Quinn; S Culine; CN Sternberg; Y Mai; CH Poehlein; RF Perini; DF Bajorin

doi:10.1056/NEJMoa1613683

Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma

J Bellmunt, Ronald de Wit, DJ Vaughn, Y Fradet, JL Lee, L Fong, NJ Vogelzang, MA Climent, DP Petrylak, TK Choueiri, A Necchi, W Gerritsen, H Gurney, DI Quinn, S Culine, CN Sternberg, Y Mai, CH Poehlein, RF Perini, DF Bajorin

Medical Oncology

Research output: Contribution to journal › Article › Academic › peer-review

2949 Citations (Scopus)

Original language	Undefined/Unknown
Pages (from-to)	1015-1026
Number of pages	12
Journal	New England Journal of Medicine
Volume	376
Issue number	11
DOIs	https://doi.org/10.1056/NEJMoa1613683
Publication status	Published - 2017

Research programs

EMC OR-01

Access to Document

10.1056/NEJMoa1613683

http://hdl.handle.net/1765/108350

Cite this

Bellmunt, J., de Wit, R., Vaughn, DJ., Fradet, Y., Lee, JL., Fong, L., Vogelzang, NJ., Climent, MA., Petrylak, DP., Choueiri, TK., Necchi, A., Gerritsen, W., Gurney, H., Quinn, DI., Culine, S., Sternberg, CN., Mai, Y., Poehlein, CH., Perini, RF., & Bajorin, DF. (2017). Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma. New England Journal of Medicine, 376(11), 1015-1026. https://doi.org/10.1056/NEJMoa1613683

@article{c57ec0add2834bf48ee3d5f451a0216e,

title = "Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma",

author = "J Bellmunt and \{de Wit\}, Ronald and DJ Vaughn and Y Fradet and JL Lee and L Fong and NJ Vogelzang and MA Climent and DP Petrylak and TK Choueiri and A Necchi and W Gerritsen and H Gurney and DI Quinn and S Culine and CN Sternberg and Y Mai and CH Poehlein and RF Perini and DF Bajorin",

year = "2017",

doi = "10.1056/NEJMoa1613683",

language = "Undefined/Unknown",

volume = "376",

pages = "1015--1026",

journal = "New England Journal of Medicine",

issn = "0028-4793",

publisher = "Massachussetts Medical Society",

number = "11",

}

Bellmunt, J, de Wit, R, Vaughn, DJ, Fradet, Y, Lee, JL, Fong, L, Vogelzang, NJ, Climent, MA, Petrylak, DP, Choueiri, TK, Necchi, A, Gerritsen, W, Gurney, H, Quinn, DI, Culine, S, Sternberg, CN, Mai, Y, Poehlein, CH, Perini, RF & Bajorin, DF 2017, 'Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma', New England Journal of Medicine, vol. 376, no. 11, pp. 1015-1026. https://doi.org/10.1056/NEJMoa1613683

TY - JOUR

T1 - Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma

AU - Bellmunt, J

AU - de Wit, Ronald

AU - Vaughn, DJ

AU - Fradet, Y

AU - Lee, JL

AU - Fong, L

AU - Vogelzang, NJ

AU - Climent, MA

AU - Petrylak, DP

AU - Choueiri, TK

AU - Necchi, A

AU - Gerritsen, W

AU - Gurney, H

AU - Quinn, DI

AU - Culine, S

AU - Sternberg, CN

AU - Mai, Y

AU - Poehlein, CH

AU - Perini, RF

AU - Bajorin, DF

PY - 2017

Y1 - 2017

U2 - 10.1056/NEJMoa1613683

DO - 10.1056/NEJMoa1613683

M3 - Article

C2 - 28212060

SN - 0028-4793

VL - 376

SP - 1015

EP - 1026

JO - New England Journal of Medicine

JF - New England Journal of Medicine

IS - 11

ER -